Yong-Mei Cha

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Yong-Mei Cha sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed upper half by trial count

Yong-Mei Cha: 2 sponsored US clinical trials, 1 recruiting.

Yong-Mei Cha sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Bradycardia, with 1 trials.

Mid-pack sponsor footprint

Yong-Mei Cha is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Yong-Mei Cha pipeline

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Bradycardia (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yong-Mei Cha: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Yong-Mei Cha sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Yong-Mei Cha1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Yong-Mei Cha sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yong-Mei Cha sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Yong-Mei Cha page

2 registered trials is a research-attention snapshot, not an endorsement of Yong-Mei Cha or any single study.

  • 1 of Yong-Mei Cha's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Bradycardia is the condition Yong-Mei Cha studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bradycardia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Yong-Mei Cha pipeline card: 2 registered trials from official public datasets.Report a data error.